Mingbei Pharmaceutical

Mingbei Pharmaceutical is an innovative biotechnology company based in Shanghai, specializing in the development of next-generation nucleic acid drug delivery systems. Founded in 2021 by Dr. Lin Hui, a former senior scientist and Director of Chemistry at Alnylam Pharmaceuticals, the company focuses on creating proprietary lipid nanoparticle (LNP) and ligand-conjugation platforms. Its technology aims to overcome the delivery barriers to both liver and extra-hepatic tissues, such as the lungs and central nervous system, to enable targeted siRNA and mRNA therapeutics. Mingbei targets unmet medical needs in rare diseases, oncology, and metabolic disorders and has secured significant early-stage funding from prominent venture capital firms including BioTrack Capital and Legend Capital.